Abstract: The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

Abstract: The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

Abstract: The high-nitrogen compound of the formula was prepared. Pyrolysis of the compound yields carbon nitrides C2N3 and C3N5. The carbon nitrides vary in their density, texture, and morphology.

Abstract: The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

Abstract: A compound of the formula (I) wherein n is preferably 3; G1, G2, G3 and G4 are independently of one another e.g. C1–C4alkyl; A1 is e.g. hydrogen or methyl; A2 is e.g. methylene; A3? and A3? are e.g. C1–C4alkyl; A4 is e.g. C1–C8alkyl; Y is e.g. a group of the formula (IV) ?wherein R1 is e.g. hydrogen or methyl, R2 is e.g. methylene, R3? and R3? are e.g. C1–C4alkyl and R4 is e.g. hydrogen or C1–C8alkyl; and Z is e.g. a group of the formula (VI) ?with A10? and A10? being independently of one another e.g. hydrogen or C1–C4alkyl and A11? and A11? being independently of one another e.g. C2–C6alkylene, is useful for stabilizing an organic material against degradation induced by light, heat or oxidation.

Abstract: A process for producing predominantly cis nucleosides or nucleoside analogues and derivatives of formula (A): wherein R1 is a pyrimidine base or a pharmaceutically acceptable derivative thereof and Q is oxygen, carbon or sulphur, comprising a coupling step of the pyrimidine base with a molecule of formula (B) described herein in a suitable coupling solvent, in the presence of catalytic amounts of an element or combination of elements of groups IB or IIB of the periodic table, a tertiary amine and a Lewis acid to obtained an intermediate of formula (D) which is deprotected in the subsequent step to generate the product of formula (A).

Abstract: Phenylsulfonyl ureas are disclosed for controlling harmful plants in crops of useful plants. Also disclosed are processes for the preparation of phenylsulfonyl ureas, and their use as herbicides and plant growth regulators.

Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-? activity.

Abstract: This invention relates to triazine compounds of formula (I): R1 is , aryl, or heteroaryl; each of R2, R4, and R5, independently, is Rc, halogen, nitro, nitroso, cyano, azide, isothionitro, SRc, or ORc; R3 is Rc, alkenyl, alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, ORc, OC(O)Rc, SO2Rc, S(O)Rc, S(O2)NRcRd, SRc, NRcRd, NRcCORd, NRcC(O)ORd, NRcC(O)NRcRd, NRcSO2Rd, CORc, C(O)ORc, or C(O)NRcRd; n is 0, 1, 2, 3, 4, 5, 6, or 7; X is O, S, S(O), S(O2), or NRc; Y is a covalent bond, CH2, C(O), C?N—Rc, C?N—ORc, C?N—SRc, O, S, S(O), or S(O2); Z is N; and W is O, S, S(O), S(O2), NRC, or NC(O)Rc; in which each of Ra and Rb, independently, is H, alkyl, aryl, heteroaryl; and each of Rc and Rd, independently, is H, alkyl, or alkylcarbonyl.

Abstract: The present invention relates to highly compatible, high molecular weight hydroxyphenylbenzotriazole UV-absorbers and for their use in protecting plants in green houses and the protection of foodstuffs, beverages, pharmaceuticals, cosmetics, personal care products, shampoos and the like from the deleterious effects of ultraviolet radiation. It has been found that certain highly compatible, high molecular weight hydroxyphenylbenzotriazole UV-absorbers are especially effective towards this end when incorporated in the containers or films in which such materials are stored.

Abstract: It is an object of the present invention to provide a novel material that can be used for manufacturing a light-emitting element. A triazine derivative according to the present invention is represented by a general formula (1). In the general formula (1), R1 to R12 are individually any one of hydrogen, an alkyl group, an alkoxy group, a halogeno group, acyl group, an alkoxycarbonyl group, an aryl group, and a hetero cyclic ring, or R1 and R2, R3 and R4, R5 and R6, R7 and R8, R9 and R10, and R11 and R12 are individually bonded to form a ring. It is preferable that the heterocyclic ring has a monocyclic structure of a five- or six-membered ring, or a polycyclic structure including any one or both of a five-membered ring and six-membered ring, and includes any atom of nitrogen, oxygen, and sulfur.

Abstract: An agricultural composition comprising the chemical formula, or salt thereof, of: wherein Rx is —NH2, —OH, halogen, akylamino, SR1, carboxyalkyl, carboxy, or a sulfonamide moiety, wherein R1 is a H or a C1 to C6 alkyl moiety, and Ry and Rz, independently, are electron donating groups and an agriculturally acceptable carrier.

Abstract: The present invention provides a new carbazole based compound represented by the following formula (1): wherein R is a substituent selected among a hydrogen atom, an alkyl group, an alkyl ether group, a sulfoamino group, a carbon cyclic group, a heterocyclic group and an aromatic cyclic group, “n” is integer, where at least one substituent other than the hydrogen atom are introduced and the each substituent may be the same or different.

Abstract: Compounds that selectively inhibit inappropriate kinase activities and methods for their preparation are disclosed. In one embodiment, the compounds are represented by Formula I, As selective inhibitors of inappropriate kinase activities, the compounds of the present invention are useful in the treatment of conditions associated with such activity, including, but not limited to, inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are methods of inhibiting inappropriate kinase activities and methods of treating conditions associated with such activities.

Abstract: Triazine derivatives of formula (I), which exhibit pharmacological activity at estrogen receptors alpha (ER alpha) and beta (ER beta) are described herein. The described invention also includes compositions and medicaments containing the triazine derivatives as well as processes for the preparation and use of such compounds, compositions and medicaments.

Abstract: Colorant compositions, and intermediate chemical compositions of colorant compositions are made from 1,2,4-triazolo[4,3-a][1,3,5]triazine-3,5,7-substituted compounds.

Abstract: N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-? expression utilizing compounds of the present invention are also disclosed.

Abstract: The invention relates to novel substituted thienyl(amino)sulphonylureas of the general formula (I) in which A, Q, R1, R2, R3, R4 and R5 are each as defined in the description, to processes for their preparation and to their use as herbicides.

Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.

Abstract: The compounds of the formula (I) and their salts where the radicals R1 to R4, A1, A2, L0, X and n are as defined in claim 1 are suitable as herbicides and plant growth regulators and can be prepared by processes as claimed in claim 6.

Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which inhibits telomerase. It also relates to novel chemical compounds as well as their therapeutic application in humans.

Abstract: The present invention includes a salt compound having the chemical formula: having a tricyclic structure with the third ring having either six or seven atoms.

Abstract: Chemical compounds having a bis(triazolo)triazine structure, including complexes and salts thereof, may be useful in either an intermediate or final product.

Abstract: Disclosed are compounds of the formulae wherein, provided that at least one of R1, R2, R3, R4, R5, and R6 is a hydrogen atom, and provided that at least one of R1, R2, R3, R4, R5, and R6 is not a hydrogen atom, R1, R2, R3, R4, R5, and R6 each, independently of the others, is (i) a hydrogen atom, (ii) an alkyl group, (iii) an aryl group, (iv) an arylalkyl group, or (v) an alkylaryl group. Also disclosed are phase change ink compositions comprising a colorant and a phase change ink carrier comprising a material of this formula.

Abstract: The invention is directed to compounds of Formulae I, II, III or IV: 1

Abstract: The present invention relates to compounds of formula (I), in which B, D, E, G, X, Y, Z, R1, R2 and s have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of formula (I) are valuable pharmacologically active compounds. They are vitronectin receptor antagonist and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or prolifertion of cells of the vascular smooth musculature.

Abstract: The present invention relates to novel compounds represented by the formula (1): wherein R1 and R2, independently, represent —NH2, NH(C1-C4alkyl), —N(C1-C4alkyl)2, —NH(C2-C4hydroxyalkyl), —N(C2-C4hydroxyalkyl)2, —N(C1-C4alkyl)(C2-C4hydroxyalkyl), —NH(C1-C4alkoxy-C2-C4hydroxyalkyl), —N(C1-C4alkoxy-C2-C4hydroxyalkyl)2, —N(C1-C4alkoxy-C2-C4hydroxyalkyl)(C1-C4alkyl), —N(C1-C4alkkoxy-C2-C4hydroxyalkyl)(C2-C4hydroxyalkyl), NH(C1-C4alkoxy-C1-C4-alkoxy-C1-C4alkyl), —N(C1-C4alkoxy-C1-C4alkkoxy-C1-C4-alkyl)2, —N(C1-C4alkoxy-C1-C4alkoxy-C1-C4-alkyl)(C1-C4alkyl), —N(C1-C4alkoxy-C1-C4alkoxy-C2-C4-alkyl)(C2-C4hydroxyalkyl) —NH(C5-C7cycloalkyl), —N(C5-C7cycloakyl)2, —NH(C6-C10aryl), NH(C7-C13-aralkyl) or a morpholino, piperidino or pyrrolidino residue; halogen or —OC1-C4alkyl, which is unsubstituted or substituted by hydroxy or —C1-C4alkoxy, a process for their preparation and their use as fluorescent whitening agents (FWA'

Abstract: The present invention relates to compounds of the formulae I and Ia in which X, Y, W, Wa, G and Ga have the meanings given in the patent claims, and their physiologically tolerable salts and their prodrugs, their preparation, their use, in particular as pharmaceutical active compounds, and pharmaceutical preparations comprising them. The compounds of the formula I are vitronectin receptor antagonists and can be employed, for example, as inhibitors of bone resorption and for the treatment of osteoporosis.

Abstract: Triazine derivatives of formula (I), which exhibit pharmacological activity at estrogen receptors alpha (ER alpha) and beta (ER beta) are described herein. The described invention also includes compositions and medicaments containing the triazine derivatives as well as processes for the preparation and use of such compounds, compositions and medicaments.

Abstract: Disclosed are compounds of the formulae 1

Abstract: Hindered amine compounds which are substituted by a long hydrocarbon chain are useful in a number of applications where the solubility or compatibility afforded by said substitution is needed. This is seen particularly for example with white, dyed, dipped, unscented and/or scented candle wax which is effectively stabilized against discoloration and fading by the incorporation therein of a long chain hindered amine alone or in combination with a UV absorber and/or an antioxidant.

Abstract: The present invention also provides a general method to whereby mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY1 receptor. The present invention provides novel, potent, non-peptidic antagonists of NPY receptors, particularly, the NPY1 receptors, designed from a selection of mono-, bi-, or tri-cyclic heterocyclic cores. This invention relates to novel compounds, compositions, and methods for the treatment of physiological disorders associated with an excess of neuropeptide Y. The novel compounds encompassed by the present invention are those of the formula I-XV.

Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Abstract: The present invention provides a new carbazole based compound represented by the following formula (1): 1

Abstract: The present invention relates to cancer therapy and to novel anticancer agent having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.

Abstract: The present invention includes a precursor compound pertaining to a 1,2,4-Triazolo[4,3-a][1,3,5]Triazine compound, particularly a 1,2,4-Triazolo[4,3-a][1,3,5]Triazine-3,5,7-Triamine, and novel fused ring structures such as triazolyl-tetrazinyl-aminotriazine compounds, and complexes and salts thereof, and other such chemical structures.

Abstract: Amino-pyrimidine and amino-triazine derivatives having 5-HT7 antagonist activity for the treatment of sleeping disorders, depression, schizophrenia, anxiety, obsessive compulsive disorders, circadian rhythm disorders, ocular disorders and/or centrally and peripherally mediated hypertension are provided.

Abstract: The present invention relates to substituted benzothiazole derivitives and to their pharmaceutically acceptable salts useful for the treatment of diseases related to the adenosine receptor.

Abstract: This invention concerns HIV replication inhibitors of formula 1

Abstract: A compound of formula (I) wherein n is e.g. a number from 2 to 50; R5′ and R5″ are e.g. a group of formula (II); G1, G2, G3 and G4 are e.g. C1-C4akyl; R1 is e.g. hydrogen or C1-C4alkyl; R2 is e.g. methylene; R3′ is e.g. hydrogen and R3″ is e.g. hydrogen or C1-C4alkyl; R4 is e.g. C2-C8alkylene; and X is e.g. —N(R7)R8) with R7 and R8 being independently of one another hydrogen or C1-C8alkyl, is useful for stabilizing an organic material against degradation induced by light, heat or oxidation.

Abstract: Hindered amine compounds which are substituted by a long hydrocarbon chain are useful in a number of applications where the solubility or compatibility afforded by said substitution is needed. This is seen particularly for example with white, dyed, dipped, unscented and/or scented candle wax which is effectively stabilized against discoloration and fading by the incorporation therein of a long chain hindered amine alone or in combination with a UV absorber and/or an antioxidant.

Abstract: Hindered amine compounds which are substituted by a long hydrocarbon chain are useful in a number of applications where the solubility or compatibility afforded by said substitution is needed. This is seen particularly for example with white, dyed, dipped, unscented and/or scented candle wax which is effectively stabilized against discoloration and fading by the incorporation therein of a long chain hindered amine alone or in combination with a UV absorber and/or an antioxidant.

Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-&bgr; activity.

Abstract: This invention is directed to triazine derivatives which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

Abstract: The invention relates to new s-triazine derivatives of the formula (I): in which R1 represents an —NH—F radical, wherein F is a screening chromophore; R2 represents an —NH—Z—W radical, wherein Z is a divalent radical providing the connection between —NH— and —W, and W is a silicone-containing radical; and R3 is R1, R2, a linear or branched C1-C20 alkyl radical, a linear or branched C2-C20 hydroxyalkyl radical, a linear or branched C1-C20 alkoxy radical, an NHR8 radical or an N(R8)2 radical, with R8 being a linear or branched C1-C20 alkyl radical. The compounds of the invention are useful as organic sunscreen agents in cosmetic compositions intended for the protection of the skin and the hair against ultraviolet radiation. The invention also relates to the use of the compounds in cosmetic applications and to cosmetic compositions with improved properties containing these compounds.

Abstract: The present invention relates to cancer therapies using novel anticancer agents with a specific mechanism of action. The invention also relates to novel chemical compounds and their therapeutic application in man.

Abstract: A product obtainable by 1) reacting a compound of the formula (&agr;) with a compound of the formula (&bgr;) in a molar ratio of 1.2:1 to 1.4:1; 2) reacting the end groups of the formula (&ggr;) being present in the product of the reaction 1) with e.g. dibutylamine in a molar ratio of 2:1.7 to 2:3; the reactions 1) and 2) being carried out in an organic solvent in the presence of an inorganic base; and 3) transferring the groups of the formula being present in the product of the reaction 2) to groups of the formula said transfer being carried out by reacting the product of the reaction 2) with a hydroperoxide in a hydrocarbon solvent in the presence of a peroxide decomposing catalyst. The products obtained are useful as light stabilizers, heat stabilizers and oxidation stabilizers for organic materials, in particular synthetic polymers such as polyolefins.

Abstract: An alignment structure useful in a liquid crystal display device comprising a substrate having disposed thereon an oriented film of a lyotropic nematic liquid crystalline material. Particularly useful lyotropic materials include a class of nematic liquid crystalline compounds known as chromonics. The substrates can be made by coating the lyotropic liquid crystal material onto the substrate to provide an oriented film of the lyotropic material. The alignment structure can also include one or more polarizing dyes or other additives and can thus be made to perform polarizing, retarding and/or color filtering functions in addition to alignment and orientation functions. Liquid crystal displays containing such alignment structures and methods of making such displays are also described.

Abstract: Triazole compounds of the following formula: where Ar1, A, B and Ar2 have the meanings given in the description, possess a high affinity for the dopamine D3 receptor and can therefore be used for treating diseases which respond to dopamine D3 ligands.

Abstract: Polyaminotriazines represented by formula (I) can be prepared by conducting a reduction alkylamination of a tetramethylpiperidone with a diamine represented by formula (IIb), NH2—R—NH2, in the presence of a hydrogenating catalyst, removing the catalyst upon completion of the reaction to obtain an unrefined crude product (A); and, conducting a polycondensation reaction of the unrefined crude product (A) and a dichlorotriazine in an aromatic solvent and in the presence of an inorganic base.